On March 1, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. and Zhejiang Terex Pharmaceutical Co., Ltd. signed a global strategic cooperation agreement, announcing that the two sides will carry out cooperation in various aspects in the field of tumor immunotherapy and nano-antibody drugs, with strong cooperation, complementary advantages and win-win cooperation. Dr. Wan Yakun, chairman of Rocky Biology, and Dr. Wu Youling, chief executive officer and chairman of Trisys Pharmaceutical attended the ceremony and signed. Xiong Quanlong, deputy director of the Standing Committee of Huzhou Municipal People's Congress and secretary of the Party Committee of the Development Zone, attended the ceremony and delivered an important speech.

Loki Biology is a pioneer and leader in the research and development of nanoantibody drugs in China. The company is committed to breaking the patent barrier of international nanoantibody, building China's nanoantibody drug brand, and promoting the innovative development of domestic nanoantibody drugs. Loki has accumulated rich experience in the screening of new targets of nanoantibodies, the discovery of new drugs, and the construction of bispecific antibodies, and has built a global leading technology platform. Dr. Wan Yakun, chairman of Rocky Biology, said: "Terex Pharmaceuticals is committed to the development of tumor antibody drugs. It has a world-class CMC team and a world-leading CMC capability. As the leaders in their respective fields in China, we believe that through this signing, the two sides can strengthen cooperation and complement each other, create a world-influential Chinese nano-antibody drug brand, and promote the development of China's nano-antibody drug industry."

Terex Pharmaceutical is committed to the development of tumor antibody drugs, integrating research and development, pilot scale up and commercial production. It has a world-class monoclonal antibody product development team, and has established the only large-scale commercial biological drug production base in China that meets the international (US/FDA, EU/EMA and ICH) cGMP standards (4 × 5000L=20000L), is also the first Chinese pharmaceutical enterprise to successfully complete the production of a single batch of 5000L monoclonal antibody products, and is the first Chinese pharmaceutical enterprise to successfully apply for biological similar drugs in the FDA of the United States. The 5000L scale monoclonal antibody product (TRS003) has started the international (US/China) phase 3 clinical research. "Loki Biotech focuses on the development of nanoantibodies, and has unique advantages. The cooperation with Loki Biotech is the reasonable integration of upstream and downstream advantageous resources, and the mutual support and trust of both sides." Dr. Wu Youling, CEO and Chairman of Trisys Pharmaceutical, said, "We hope to provide more innovative drugs for cancer treatment for patients through the joint efforts of both sides, and benefit the people."

The good wind can send me up to the blue clouds. With the rise of nano-antibody drugs in the global antibody drug industry, we believe that Loki Biotech can fully grasp the opportunity of the development of the era, rely on its own advantages, develop more nano-antibody drugs to meet the actual needs of patients, and realize the good wish of "nano-antibody to start human health in the future".

About novamab

Shanghai Novamab Biomedical Technology Co., Ltd. (Novamab) is committed to the research and development of nanoantibody innovative drugs, aiming to provide patients with faster, safer and more effective innovative drugs. The company has built a large-scale camel breeding base, a platform-based new drug discovery platform, a mature antibody humanization and affinity maturity platform, a bispecific nanoantibody design platform, a highly expressed cell line construction platform and a complete process development platform. The company's product pipeline covers tumor immunotherapy, autoimmune diseases, ophthalmic diseases and Car-T treatment, with more than 30 products。